Big Drug Recall Warning Hits Montana

Man, as if we didn't have enough to worry about, now we have to double-check our medicine cabinets to make sure we're not taking anything bad for us.

A new recall has revealed that a popular antidepressant could be linked to cancer.

FDA Announces Recall on Popular Antidepressant

According to a recent FDA notice, a voluntary recall was announced for Duloxetine Delayed-Release Capsules, USP, 30mg, 1000 Capsule bottles.

The medicine is prescription only and distributed by Breckenridge Pharmaceuticals, Inc.

ALSO READ: Who Owns the Big Banana Car Recently Pulled Over by Montana Highway Patrol?

The reason for the recall is due to the "presence of N-nitroso-duloxetine impurity above FDA recommended interim limit."

According to the FDA, "Nitrosamine impurities may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time."

Get our free mobile app

Apparently, the source of nitrosamines can be traced back to the manufacturing process, chemical structure, and "even the conditions in which they are stored or packaged."

Here's the information you need to know about the nationwide recall according to the FDA:

Duloxetine Delayed-Release Capsules, USP, 30 mg

Size: 1,000 capsules
Expiration date: April 2027, with lot code: 241180C
Affected quantity: 14,729 bottles
Duloxetine Delayed-Release Capsules, USP, 60 mg

Sizes: 90 capsules and 1,000 capsules
Expiration date: November 2026, with lot code: 232311
Expiration date: January 2027, with lot code: 240316
Expiration date: February 2027, with lot codes: 240317, 240318, 240315C, 240373C, 240370C, 240375C, and 240413C
Expiration date: April 2027, with lot codes: 240978C and 241052C
Expiration date: May 2027, with lot code: 241074C
Affected quantity: 359,676 bottles